17,261 trials
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieve American College of Rheumatology Response of 20 (ACR20) — 53.4; 44.9; 40.9 Percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieve American College of Rheumatology Response of 20 (ACR20 ) in Association With the Presence or Absence of the HLA-DRB1 *4 Allelic…
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IIIA Colon Cancer
Primary: Objective Response (CR or PR) as Determined by the RECIST Criteria — 0; 0 participants
Relapsing-remitting Multiple Sclerosis · RRMS
Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…
Stomach Neoplasms · Esophageal Neoplasms
Primary: Overall Response Rate (ORR) — 39.1 percentage of participants
Hepatocellular Carcinoma
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
Amyotrophic Lateral Sclerosis
Primary: Safety Outcomes: Frequency of Adverse Events — 49; 24; 42 Total Number of Adverse Events — p=0.06
Multiple System Atrophy
Primary: Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II) — 7.2; 7.8 units on a scale — p=0.6984
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
Breast Neoplasms · Neoplasm Metastasis
Primary: Patient Benefit Rate at 12 Weeks — 30.0; 34.2; 41.9 percentage of participants
Gastrointestinal Diseases
Primary: Absence of Gastrointestinal (GI) Leak — 72; 81; 38 participants
Thrombosis · Hip Replacement
Primary: Adjudicated Incidence of VTE — 29.0; 20.3; 15.7; 11.5 percentage of participants with VTE — p=0.003
Anthrax
Primary: Toxin Neutralizing Antibody (TNA) Level at Day 63 — 56.8; 100; 100; 90.2 percentage of participants
Ovarian Cancer
Primary: Progression-free Survival — 23.7 Months